Oral Peptide Incretin Delivery
Formulation and absorption-enhancement techniques that make injectable-grade incretin peptides, including multi-receptor co-agonists, orally bioavailable, allowing the same molecule to be given as a pill rather than an injection.
Developed mainly in: United Kingdom and United StatesImpacting: North America, Europe, China and Rest of Asia
Viking Therapeutics has started Phase 3 testing of VK2735, an orally dosed dual GLP-1/GIP receptor agonist, in people with obesity. The pill version follows earlier mid-stage work on both oral and injectable formats of the same molecule. No new efficacy figures accompanied the announcement; enrolment and endpoint details define the registrational program.
This is one of 32 signals scored today.
Track Them Free For 14 Days →Since we flagged this
First flagged
14 October 2026 · score 5.0/10
Corroborating sources since flagging
4
Latest signals
Tracked from 2 signals, each traced to its source.
- Well-funded obesity startup halts Phase 2 oral GLP-1 study, blaming market shift
Endpoints · 28 Oct 2026
- Viking begins late-stage trials of oral obesity drug VK2735 in patients
Prnewswire · 14 Oct 2026
In the full record
Evolution
Score over time, Score Jumps and how the evidence built up since the first signal.
Thesis
Paradigm Shift, Commercial Viability, signal strength and the driver of the change.
Why this innovation matters
The full analysis: what is shifting, who is affected and the second-order effects.
Forecasted Hypothesis
What would strengthen this innovation, and what would weaken it.
Exposure
Companies and publicly listed stock symbols linked to this innovation.
Every signal
Each signal with its date, score, flags and original source.
Open the full record free for 14 days → No card needed.
More in Biotech
Other innovations the engine is currently tracking in this industry.
- Microbial Milk Protein Fermentation6.5/ 10 · 2 signals
- Clinical Genome-Editing Therapeutics7.6/ 10 · 8 signals
- Cis-Regulatory Element Editing6.5/ 10 · 2 signals
- Agent-Operated Self-Driving Laboratories6.5/ 10 · 2 signals
- Individualised Neoantigen mRNA Immunotherapy6.3/ 10 · 6 signals
- Generative Molecular Design Platforms6.5/ 10 · 4 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.